ArticleScientific reports2026
Epidemiology and prevention of HPV-driven cervical cancer in urban-rural China: a population-based study of 60,280 women.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ultrasound-Clinical Machine Learning Models for Differentiating Early Cervical Cancer from Myoma: A Retrospective Exploratory Study.Journal of clinical medicine · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer continues to pose a significant public health burden in China, where marked differences persist in HPV infection rates and screening participation between urban and rural populations. We investigated HPV epidemiology and evaluated prevention approaches in Putian, a southeastern Chinese region representative of broader demographic patterns. This cross-sectional study analyzed screening results from 60,280 women aged 35-64 years who participated in Putian's free cervical cancer screening program between 2021 and 2023. We employed HPV genotyping (14 high-risk subtypes), liquid-based cytology (TCT), and histopathological examination to assess infection rates, subtype distribution, and screening effectiveness. The data provided insights into both epidemiological patterns and diagnostic performance within this population. The overall human papillomavirus (HPV) infection prevalence was 9.27% (95% CI: 9.04-9.50), with HPV 52 (35.61%), HPV 58 (16.56%), and HPV 16 (12.38%) emerging as the most prevalent genotypes. Cervical cancer incidence peaked in women aged 55-59 (95 cases per 100,000), with a secondary peak observed in the 50-54 age group (89 cases per 100,000). In addition, a concerning early-onset pattern appeared in the 40-44 age group (46 cases per 100,000). The national incidence rate averaged 56 cases per 100,000. HPV 16/18 infections accounted for the majority of cervical cancer cases, with HPV 58/33/52 representing secondary high-risk genotypes. ThinPrep cytologic test (TCT) screenings revealed clinically significant underdiagnosis and overdiagnosis rates. Only 1.33% of women participated in self-screening initiatives. Urban-rural disparities in HPV 52/58/33 prevalence persist alongside low screening rates, underscoring the urgency of implementing targeted vaccination strategies, particularly the 9-valent HPV vaccine, and adopting advanced triage methods such as methylation testing in Putian.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.